Journal
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
Volume 136, Issue 14, Pages 5501-5507Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ja501731p
Keywords
-
Categories
Funding
- BBSRC/EPSRC [E021611]
- BBSRC [BB/E021611/1, BB/L01386X/1, BB/I014039/1, BB/I014373/1] Funding Source: UKRI
- EPSRC [EP/F066104/1, EP/K03927X/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/L01386X/1, BBS/B/07071, BB/I014039/1, BB/I014373/1, BB/E021611/1] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [EP/K03927X/1, EP/F066104/1] Funding Source: researchfish
Ask authors/readers for more resources
Mupirocin, a clinically important antibiotic produced via a trans-AT Type I polyketide synthase (PKS) in Pseudomonas fluorescens, consists of a mixture of mainly pseudomonic acids A, B, and C. Detailed metabolic profiling of mutant strains produced by systematic inactivation of PKS and tailoring genes, along with re-feeding of isolated metabolites to mutant stains, has allowed the isolation of a large number of novel metabolites, identification of the 10,11-epoxidase, and full characterization of the mupirocin biosynthetic pathway, which proceeds via major (10,11-epoxide) and minor (10,11-alkene) parallel pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
